Currently, there are 119.16M common shares owned by the public and among those 98.75M shares have been available to trade.
The company’s stock has a 5-day price change of 43.43% and 71.70% over the past three months. WVE shares are trading 62.18% year to date (YTD), with the 12-month market performance up to 50.55% higher. It has a 12-month low price of $3.50 and touched a high of $7.67 over the same period. WVE has an average intraday trading volume of 889.82K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 44.74%, 40.41%, and 50.49% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Wave Life Sciences Ltd. (NASDAQ: WVE) shares accounts for 75.31% of the company’s 119.16M shares outstanding.
It has a market capitalization of $1.02B and a beta (3y monthly) value of -1.13. The earnings-per-share (ttm) stands at -$0.58. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.25% over the week and 6.78% over the month.
Earnings per share for the fiscal year are expected to decrease by -95.47%, and 5.16% over the next financial year.
Looking at the support for the WVE, a number of firms have released research notes about the stock. B. Riley Securities stated their Buy rating for the stock in a research note on September 19, 2024, with the firm’s price target at $11. JP Morgan coverage for the Wave Life Sciences Ltd. (WVE) stock in a research note released on September 09, 2024 offered a Overweight rating with a price target of $10. Wells Fargo was of a view on May 15, 2024 that the stock is Overweight, while Leerink Partners gave the stock Outperform rating on December 19, 2023, issuing a price target of $5- $12. Raymond James on their part issued Outperform rating on July 05, 2023.
